Nabriva Therapeutics plc

Nabriva Therapeutics is a commercial-stage biopharmaceutical company engaged in the development of novel antibiotics to treat serious infections. Nabriva Therapeutics has two products: Xenleta (lefamulin), recently approved by the FDA for both Oral and IV use and CONTEPO (fosfomycin) for injection, they submitted an NDA for CONTEPO, a potential first-in-class epoxide antibiotic in the United…More States for complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP). Their corporate headquarters are in Dublin, Ireland with offices and labs located in Vienna, Austria and King of Prussia, PA.